Search

Nedosiran

[A261685] Nedosiran was approved by the FDA on October 2^nd, 2023, under the brand name RIVFLOZA to lower urinary oxalate levels in children 9 years of age and older and adults with primary … Nedosiran is an RNA interference targeting hepatic lactate dehydrogenase, the enzyme responsible for the conversion of glyoxylate to oxalate.

Ancestim

It is a 166 amino acid protein produced by E. coli with an amino acid sequence that is identical to the natural sequence predicted from human DNA sequence analysis, except for the addition of an N-terminal … [T68] It was also approved by Health Canada in 1999 but it is currently under the status of canceled post-market.[L1087]

Magnesium Aluminum Silicate

It is refined to a powder for use in cosmetic and pharmaceutical applications as an absorbent, anticaking agent, opacifying agent, viscosity-increasing agent, suspending agent, tablet and capsule disintegrant

Pilocarpine

[A262016, A262036] Pilocarpine is associated with parasympathomimetic effects by selectively working on muscarinic receptors.

Tigecycline

Food and Drug Administration (FDA) on June 17, 2005. … It was developed in response to the growing prevalence of antibiotic resistance in bacteria such as Staphylococcus aureus. It was granted fast-track approval by the U.S.

Telaprevir

Approved in May 2011 by the FDA, Incivek was indicated for the treatment of HCV genotype 1 in combination with [DB00811], [DB00008], and [DB00022] [FDA Label]. … Telaprevir is an inhibitor of NS3/4A, a serine protease enzyme, encoded by HCV genotype 1 [FDA Label].

Racepinephrine

It is an active ingredient in oral inhalation over-the-counter products as racepinephrine hydrochloride. … It is a bronchodilator used in the temporary relief of mild symptoms of intermittent asthma including wheezing, tightness of chest and shortness of breath.

Omacetaxine mepesuccinate

Then in March 2006, it received Orphan Drug status from the FDA for the treatment of CML. … In November 2006, omacetaxine mepesuccinate, for the treatment of CML, was granted Fast Track designation by the FDA.

Ferrous ascorbate

Pralatrexate

[A246703] Pralatrexate was approved by the FDA on September 24, 2009. … [A246693] Compared to methotrexate, pralatrexate has better accumulation in cancer cells.